Upstream Bio, Inc.
UPBHealthcare|Biotechnology|US
$3.23
+0.02 (+0.62%)
Tangible Book / Share
$4.97
Cash / Share
$4.79
About
Upstream Bio, Inc. is a biotechnology company in the clinical development stage, dedicated to innovating therapies for inflammatory conditions, particularly those affecting the severe respiratory system. Its pipeline notably features verekitug, a monoclonal antibody designed to selectively target and suppress the thymic stromal lymphopoietin receptor. Beyond this, the company is actively developing treatments for severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Established in 2021, Upstream Bio maintains its operational base in Waltham, Massachusetts.
Stock Price
-86.3%(1Y)
1M
-29.0%
3M
-55.4%
6M
-64.5%
YTD
-88.1%
1Y
-86.3%
3Y
-85.3%
5Y
-85.3%
Pipeline Summary
6 total trials2
Phase 1
4
Phase 2
0
Phase 3
0
Phase 4
Active: 2Completed: 4
Active Trials (2)
A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)
NCT06966479Severe Asthma
Phase 2Active
Enrollment: 396 participants
A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD
NCT06981078Chronic Obstructive Pulmonary Disease
Phase 2Active
Enrollment: 666 participants
Key Facts
Market Cap$176.9M
Employees75 (+44% YoY)
CEOE. Rand Sutherland
IPO DateOct 11, 2024
Beta1.39
52-Week Range$2.68 – $33.68
Avg Volume777,930
ExchangeNASDAQ
Websiteupstreambio.com
Ownership
Float36.9%
Shares Outstanding54.8M
Recent Insider Trades
GRAY MICHAELSELL
Sep 16, 2026853 shares @ $5.49
Ambrose AllisonSELL
Sep 16, 2026485 shares @ $5.49
Deykin AaronSELL
Sep 16, 2026895 shares @ $5.49
Sutherland Everett RandSELL
Sep 16, 20262,095 shares @ $5.49
Houghton AdamSELL
Sep 16, 2026700 shares @ $5.49
Peers
Recent News
Analyzing Upstream Bio (NASDAQ:UPB) and Keros Therapeutics (NASDAQ:KROS)
Oct 5, 2026 · defenseworld.net
These beaten-down stocks could bounce back in January, if history is any guide
Sep 21, 2026 · marketwatch.com
Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026
Sep 8, 2026 · globenewswire.com
Upstream Bio Announces Pivotal Phase 3 Development Plans for Verekitug in Both Severe Asthma and CRSwNP
Sep 1, 2026 · globenewswire.com
Fannie Mae Announces Sale of Non-Performing Loans
Aug 19, 2026 · gurufocus.com
Data last updated: Nov 9, 2026, 04:38 AM